Newborn screening study aims to catch rare diseases at birth
NCT ID NCT03655223
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and many others. The goal is to identify affected infants before symptoms appear, allowing for prompt treatment and support. Researchers also study the impact of screening on families and evaluate the program's effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this screening program could enable earlier diagnosis and treatment for newborns with rare conditions, potentially improving their health and development.
- What could go wrong
- This is an observational screening study, not a treatment trial. Most newborns will screen negative, and positive results may cause anxiety. The long-term benefits of early diagnosis are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2018
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Newborns born in North or South Carolina who are less than 31 days old
- Ages
-
1 day to 31 days
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Newborn has newborn screening in North Carolina * Newborn lives in North Carolina or South Carolina * Newborn is less than 31 days old * Person giving consent must have legal custody of the newborn. When the mother retains custody, they must be the person to give consent. * Person giving consent must be able to interact with the online permission portal (available in English and Spanish) and give permission online Exclusion Criteria: * A newborn screening (NBS) sample is unavailable for the newborn * Insufficient NBS sample remains to conduct the screening
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for 17 alpha-hydroxylase deficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
RTI International
Research Triangle Park, North Carolina, 27709, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding common pain drugs reduce morphine needs in sickle cell crises?
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Can coconut oil and moringa rinses fight gum disease in diabetic kids?
- Gene editing offers hope for a One-Time sickle cell cure
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?